Seaport Therapeutics, Hemab Therapeutics File IPOs as Biotech Window Cracks Open

Seaport Therapeutics and Hemab Therapeutics filed for initial public offerings this week, joining Kailera Therapeutics in a cluster of biotech IPO activity that represents the first sustained filing momentum since mid-2023. Kailera priced its offering Wednesday, raising $106 million at the low end of range—a signal that institutional allocators are willing to participate, but not at premium.

Seaport, a clinical-stage neuroscience company spun out of Karuna Therapeutics, disclosed its S-1 filing Thursday with plans to list on Nasdaq. The company is developing treatments for psychiatric and neurological disorders, led by SPN-830, a Phase 3-stage therapy for post-traumatic stress disorder. Hemab, focused on hemophilia A treatments, filed Friday with no disclosed pricing terms yet. Neither company named lead underwriters in initial filings, a procedural lag that typically resolves within two weeks. Kailera, which priced at $10 per share, is developing therapies for chronic kidney disease and raised capital at a valuation that values the company at roughly 4.2x trailing twelve-month R&D spend—compressed by historical biotech IPO standards but in line with 2024's risk-off pricing environment.

The cluster matters because it breaks an 18-month drought in biotech IPO velocity. Since Q2 2023, only a handful of life sciences companies have gone public, with most venture-backed biotechs choosing private extension rounds or strategic acquisitions over public markets. The sudden filing activity suggests three possible dynamics: syndicate desks testing allocation appetite ahead of a potential spring window, companies with clinical catalysts in the next 12-18 months choosing to front-run volatile macro conditions, or venture portfolios reaching fund-life limits that force liquidity events regardless of pricing. Seaport's filing is particularly instructive—Karuna itself was acquired by Bristol-Myers Squibb for $14 billion in late 2023, and Seaport represents the neuroscience pipeline assets that didn't fit the acquirer's development strategy. Spinning out post-acquisition assets into standalone IPOs is a pattern that typically signals sponsor conviction, but also reflects limited M&A appetite for mid-stage programs in the current environment.

Allocators should watch three follow-on data points. First, whether Seaport and Hemab price within 21 days of filing or delay into Q2, which would indicate institutional pushback on valuation or terms. Second, the composition of cornerstone investors in these deals—if mutual funds or crossover hedge funds anchor the books, it signals broader risk-on rotation; if only specialist biotech funds participate, the rally is narrow. Third, post-IPO trading performance of Kailera over the next 30 days—if shares hold or trade up, the IPO window widens materially; if they break issue price, the window was a headfake. The broader venture intelligence takeaway is that biotech syndicates are testing the market, not leading it.

Seaport's Phase 3 PTSD data is expected in mid-2025, which places the IPO roughly 9-12 months ahead of a binary value catalyst—tight timing that leaves little room for clinical delays or enrollment misses.